Raman Preet Kaur1, Raja Paramjeet Singh Banipal2, Rajesh Vashistha3, Monisha Dhiman4, Anjana Munshi5. 1. Department of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, Punjab, India. 2. Guru Gobind Singh Medical College & Hospital, Faridkot, Punjab, India. 3. Max Super-Specialty Hospital, Bathinda, India. 4. Department of Biochemistry and Microbial Sciences, Central University of Punjab, Bathinda, Punjab, India. 5. Department of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, Punjab, India. Electronic address: anjana.munshi@cup.edu.in.
Abstract
BACKGROUND AND PURPOSE: Inflammation and caner are linked in a bidirectional manner. C-reactive protein (CRP) is an important inflammatory marker. The aim of the study was to test whether the inflammatory marker, CRP at the time of diagnosis of breast cancer is associated with metastasis, recurrence, and death in breast cancer patients from Malwa region of Punjab where breast cancer is widely feared. MATERIAL AND METHODS: Two hundred and forty-two breast cancer patients and 242 age and sex matched controls were included in the study. CRP levels were estimated using fully automated bio analyzer Erba200. Follow up interviews were conducted at an interval of 3, 6, 9, 12, 15, 18, 21, 24, and 27 months to determine the outcome among breast cancer patients. RESULTS: Elevated levels of CRP were found among the diseased in comparison with controls (P < 0.0001). Higher CRP levels associated significantly with poor outcome including metastasis and recurrence among breast cancer patients [P = 0.03; 95% confidence interval; odds ratio: 2.954 (0.9125-9.561)]. CONCLUSION: Elevated levels of CRP associated significantly with increased risk of breast cancer and poor outcome. CRP estimation may be a simple and inexpensive tool for the risk assessment and outcome of the disease in Malwa region of Punjab where incidence of breast cancer is reported to be very high.
BACKGROUND AND PURPOSE: Inflammation and caner are linked in a bidirectional manner. C-reactive protein (CRP) is an important inflammatory marker. The aim of the study was to test whether the inflammatory marker, CRP at the time of diagnosis of breast cancer is associated with metastasis, recurrence, and death in breast cancerpatients from Malwa region of Punjab where breast cancer is widely feared. MATERIAL AND METHODS: Two hundred and forty-two breast cancerpatients and 242 age and sex matched controls were included in the study. CRP levels were estimated using fully automated bio analyzer Erba200. Follow up interviews were conducted at an interval of 3, 6, 9, 12, 15, 18, 21, 24, and 27 months to determine the outcome among breast cancerpatients. RESULTS: Elevated levels of CRP were found among the diseased in comparison with controls (P < 0.0001). Higher CRP levels associated significantly with poor outcome including metastasis and recurrence among breast cancerpatients [P = 0.03; 95% confidence interval; odds ratio: 2.954 (0.9125-9.561)]. CONCLUSION: Elevated levels of CRP associated significantly with increased risk of breast cancer and poor outcome. CRP estimation may be a simple and inexpensive tool for the risk assessment and outcome of the disease in Malwa region of Punjab where incidence of breast cancer is reported to be very high.
Authors: Costantino Errani; Monica Cosentino; Giovanni Ciani; Lorenzo Ferra; Patricio A Alfaro; Barbara Bordini; Davide M Donati Journal: Int Orthop Date: 2021-01-04 Impact factor: 3.075
Authors: María Del Pilar Chantada-Vázquez; Antonio Castro López; María García-Vence; Benigno Acea-Nebril; Susana B Bravo; Cristina Núñez Journal: Int J Mol Sci Date: 2020-11-10 Impact factor: 5.923
Authors: Carrianne J Leschak; Janine M Dutcher; Kate E Byrne Haltom; Elizabeth C Breen; Julienne E Bower; Naomi I Eisenberger Journal: Soc Cogn Affect Neurosci Date: 2020-11-10 Impact factor: 3.436
Authors: Eda G Ramirez-Valles; Alicia Rodríguez-Pulido; Marcelo Barraza-Salas; Isaac Martínez-Velis; Iván Meneses-Morales; Víctor M Ayala-García; Carlos A Alba-Fierro Journal: Technol Cancer Res Treat Date: 2020 Jan-Dec